Hot off the press

OncologyTube produces, finds, and distributes the latest, highest quality, and engaging multimedia to a targeted audience...

Robert Gish interview

Fulgent Genetics and Helio Genomics Announce Strategic Partnership to Commercialize Early Cancer Detection Tests

Webcast of Helio Genomics Fireside Chat at the 2021 BTIG Virtual MedTech, Digital health, Life Science & Diagnostic Tools Conference

Laboratory for Advanced Medicine finance chief Aarif Nakhooda thinks customer experience is as important for colon cancer testing as it is for streaming online music or videos.

Early detection is a critical means of improving outcomes for cancer patients. When cancer is detected at stage I, patients have a 90 percent chance of survival.

The early detection of cancer has been proven to significantly improve patient survival rates and quality of life, as well as reduces the cost and complexity of cancer treatment.c

Kenneth Chahine, PhD, J.D., Discusses Company’s First Liquid Biopsy, Designed to Detect Liver Cancer at Earliest Stages, and Plans to Test for Other Cancers.

Kenneth discusses LAM's early cancer detection tests.c

Circulating tumor DNA (ctDNA), which is DNA that has been shed from ruptured cancer cells into the patient’s bloodstream, has quickly emerged as a useful biomarker for numerous cancer types.

A team of researchers affiliated with a large number of institutions in China has used a machine-learning algorithm with cancer methylation signatures to diagnose colorectal cancer.

NEW YORK – The methylation profiles of circulating tumor DNA may help diagnose colorectal cancer as well as predict patient prognosis, findings that may form the basis of a new cancer test.

Today we discuss the dissemination of DNA-methylation-based tests for non-invasive detection of cancer.

The Laboratory for Advanced Medicine has raised $86 million to further develop its blood test that can detect liver cancer. Kenneth Chahine, Chief Executive Officer of the Laboratory for Advanced Medicine, joined Cheddar to discuss.

Laboratory for Advanced Medicine (LAM), which uses artificial intelligence to identify early stages of specific cancers, is making strides to be the next big name in Orange County’s growing cluster of genomic-focused firms that provide high-tech healthcare diagnostics services....c

Kenneth Chahine is the man behind AncestryDNA, the direct-to-consumer genetic genealogy product with more than 15 million users.

With a new CEO at its helm, Laboratory for Advanced Medicine is preparing to take on the cancer-diagnostics market.

Laboratory for Advanced Medicine Inc. has raised $86 million and hired a chief executive to push new blood tests for cancer toward the market.

Richard Brand and Dr. Dhruvajyoti Roy of Laboratory for Advanced Medicine discuss the company’s blood test for early cancer detection.

FDA has granted breakthrough status to Laboratory for Advanced Medicine’s liver cancer liquid biopsy, the Irvine, California-based company said in a statement Tuesday.

A change is underway as a result of research and development into tools to detect and treat cancer early, offering patients a fighting chance and improving chances for success against the disease.c

The great promise of liquid biopsy technology is in early cancer detection. That is, it's the great future promise. Right? This past month at the annual cancer conference, ASCO, we heard about one such flagship company announcing just which technology they were going to use to do it--DNA methylation.

Nasopharyngeal carcinoma (NPC) is predominantly diagnosed using invasive testing methods like endoscopic biopsy or tissue biopsy. However, new research presented at the 2019 ASCO Annual Meeting ...

For a decade, industry researchers hypothesized that markers, such as mutations, could accurately detect cancer. However, mutation-based approaches have proven to be highly inaccurate due to the randomness of DNA mutations that occur in cancer patients. Mutations can also differ from tumor to tumor...

More than 4,700 people are diagnosed with cancer each day. About four in 10 Americans—40 percent of men and 38 percent of women—will be diagnosed with cancer at some point in their lifetime.

Using a proprietary test of cell-free DNA methylation markers, the Laboratory for Advanced Medicine (LAM), headquartered in Irvine, California, showed preliminary data demonstrating...

Commercial-stage medical technology company Laboratory for Advanced Medicine (LAM) announced positive results from a new study that evaluated DNA methylation-based marker panel for early diagnosis of nasopharyngeal carcinoma (NPC).

When a cancer cell dies, its DNA is released into the blood. Once released this DNA is referred to as cell-free DNA (cfDNA). The cfDNA retains a DNA methylation pattern that corresponds to the cell it originated from. When a “normal” cell transforms into a cancer cell...

One of the potential flaws of liquid biopsy tests that rely on the detection of tumour DNA in a patient’s blood is that the tumour has to grow to a sufficient size to shed appreciable quantities of genetic material, making detection at an early, relatively treatable stage of disease that much harder.

The Laboratory for Advanced Medicine (LAM), a biotechnology company headquartered in the US, offers non-invasive, early stage cancer detection tests that will use the IvyGene Platform. These IvyGene tests are based on detecting...

Laboratory for Advanced Medicine (LAM) says its plans for this year include developing and commercializing more of its early cancer detection tests, expanding its portfolio beyond...

A new blood test could help detect cancer as early as stage one, and one Long Island doctor says it could also save lives. The IvyGene test requires a few vials of blood to tell you if you may already be developing cancer cells in your body.

WESTBURY, N.Y., Oct. 12, 2018 /PRNewswire/ — Integrative Medicine of NY is one of the first clinical cancer facilities in the lower NY area to endorse and use the early detection and prevention lab test called IVYGENE.

An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and ...c

...the term 'cancer' is not a singular enemy; its a single term to represent hundreds of different cancer types– all unique to their location in the body and their origin...c

During this year’s AACR annual meeting we spoke to Kang Zhang, M.D., Ph.D., Founding Director of the Genomic Institute at the University of California, San Diego about the collaborative work he has been doing with...

By now you may know that there are MANY options for detecting Breast Cancer outside of traditional mammography, which may come with some dangerous side effects...c

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target.

Mission will soon begin testing their firefighters for cancer. The Mission City Council authorized the purchase of IvyGene tests, a blood test that can detect the presence of certain diseases, including...

Liver cancer can be caught at an early stage through a newly developed blood test, improving the odds for survival, according to a study led by University of California San Diego scientists.

An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and ...